Northwest Biotherapeutics, Inc.

Northwest Biotherapeutics, Inc.

Northwest Biotherapeutics is developing DCVax® personalized dendritic cell-based therapeutic vaccines for solid tumors. The Company’s lead program is DCVax®-L treatment for glioblastoma brain cancer, for which the Company has completed a Phase III trial and has applied for product approval in the U.K. The Company has also treated a variety of other solid tumors, with encouraging results, in compassionate use cases and other clinical trials.

Yes

Central Nervous System Tumors, Biotechnology, Clinical Trials, Immunotherapy